Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by Analysts

Vericel Co. (NASDAQ:VCEL - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $62.29.

Several analysts recently issued reports on the stock. Stephens reissued an "overweight" rating and issued a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Canaccord Genuity Group raised their price target on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. BTIG Research lifted their price target on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Truist Financial reissued a "buy" rating and issued a $61.00 price objective (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd.

Vericel Stock Up 0.3 %

NASDAQ:VCEL traded up $0.15 on Monday, hitting $48.09. The stock had a trading volume of 105,355 shares, compared to its average volume of 374,022. Vericel has a 52 week low of $39.12 and a 52 week high of $63.00. The business's fifty day moving average is $54.16 and its 200 day moving average is $51.73. The company has a market cap of $2.40 billion, a PE ratio of 800.97 and a beta of 1.78.

Remove Ads

Insider Buying and Selling

In other news, CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the sale, the chief executive officer now directly owns 259,997 shares in the company, valued at $11,902,662.66. The trade was a 9.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,092 shares of company stock worth $1,683,582. 5.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC lifted its stake in Vericel by 1.0% in the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company's stock valued at $100,251,000 after purchasing an additional 22,461 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of Vericel by 12.6% during the 4th quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock valued at $79,847,000 after buying an additional 162,419 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Vericel by 119.3% during the 4th quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after acquiring an additional 701,064 shares during the period. GW&K Investment Management LLC increased its holdings in Vericel by 2.4% in the 4th quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company's stock worth $69,953,000 after acquiring an additional 30,180 shares during the last quarter. Finally, William Blair Investment Management LLC raised its stake in Vericel by 66.3% in the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock valued at $69,100,000 after acquiring an additional 501,736 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.